Our findings may thus indicate that targeting of HGF, a novel microenvironmental factor involved in CLL pathogenesis, could improve conventional therapies to cure this disease by inhibiting leukemic cell growth and by restoring specific immune responses against the tumor. The gene discussed is HGF; the disease is B-cell chronic lymphocytic leukemia.